Where Progress Lives: This Month in California Life Sciences May 2026

Each month, California Life Sciences (CLS) President and CEO Mike Guerra shares what’s shaping the life sciences industry, highlights the conversations that matter most to members, and offers a window into what the CLS team is working on.

May was a reminder that California’s life sciences leadership is built on more than science alone. It takes the data that makes our case, the advocacy that protects our ecosystem, the investments that continue to flow into our state, and the community we continue to build around a shared commitment to patients.

California’s leadership, and what it takes to sustain it

This month, CLS released our 2026 Sector Report, an annual analysis of the industry’s economic footprint and momentum across the state. The headline numbers are extraordinary. California remains home to the largest and most dynamic life sciences ecosystem in the United States, generating $396 billion in total economic impact, supporting more than 1.02 million direct and indirect jobs, and contributing $20.4 billion in state and local tax revenue. The state led the nation with $5.24 billion in NIH funding and $21 billion in life sciences venture capital, a combination of foundational research and commercial innovation that reflects how California’s ecosystem continues to set the global standard.

Every region of the state contributes something distinct to that footprint. The Bay Area anchors California as one of the leading biopharma research clusters in the world, with more than 3,000 establishments and over twice the national average job density. San Diego remains one of the most research-intensive biotech hubs in the country, with deep concentrations in drug discovery, neuroscience, and oncology. Orange County leads the state in medical device manufacturing, and Los Angeles is among the fastest-growing hubs, bringing a dynamic mix of biopharma, diagnostics, and digital health companies to the table.

What the report also makes clear is that this leadership is not guaranteed. Life sciences employment in California is down 1.8 percent, and the medical devices and research, testing, and medical labs subsectors are each down 3.5 percent. Venture capital investment is up 7.6 percent in dollar terms, but the number of deals is down 10.8 percent, signaling a concentration of capital into fewer, larger rounds and leaving early-stage companies with a narrower path to funding. California’s position is real and hard-earned, and sustaining it requires continued investment in research, infrastructure, education, and the policy environment that allows our companies to grow.

Bringing California’s story to Capitol Hill

This month, CLS members traveled to Washington, D.C. for our annual Hill Day, carrying a clear message to Congress: Most Favored Nation drug pricing is the wrong prescription. Policies that import foreign price controls don’t lower costs for patients, they cut the funding that drives the next generation of cures. California’s life sciences companies have transformed patient care and made America a global leader in medical innovation, and our members were on Capitol Hill making sure that case was heard before Congress moves forward on proposals that would put that leadership at risk.

It means a great deal when members of Congress and their staff take time to hear directly from the innovators advancing life-changing treatments. I’m grateful to every legislator and staff member who engaged with our community this week. The conversations happening on the Hill will help determine whether America remains the global leader in developing the medicines and devices patients depend on, and we are thankful for the champions willing to take them on.

A continued bet on california

May also brought a powerful signal of confidence in California’s life sciences ecosystem. Pfizer opened its new San Diego R&D campus this month, a 230,000-square-foot facility purpose-built to advance the company’s oncology pipeline. The campus will bring together approximately 600 scientists and staff across discovery, biology, translational science, and early development, with an ambition of delivering eight breakthrough cancer medicines by 2030.

What stands out is not just the scale of the investment, but what it signals about where leading companies see the conditions for breakthrough science. San Diego’s depth in oncology and translational research, combined with the broader California ecosystem of academic institutions, talent, and capital, is exactly what attracts long-term commitments at this level. Investments like this are a reminder that the conditions making California the global destination for life sciences innovation are real, valuable, and worth protecting.

Welcoming new leadership and strengthening our community

This month, CLS welcomed two new members to our board of directors. Taby Ahsan, PhD brings over 20 years of experience in tissue engineering, regenerative medicine, and immunotherapy. As Vice President of Cell & Gene Therapy Operations and Director of the Center for Bioinnovation and Manufacturing at City of Hope, Dr. Ahsan plays a critical role in advancing the translation of cell and gene therapies from the lab to the clinic. Jonathan Siegrist, PhD is a senior biotechnology and diagnostics executive with over 15 years of experience leading global research and development initiatives. At QuidelOrtho, he oversees global R&D strategy, driving innovation across molecular diagnostics, microfluidic platforms, and integrated diagnostic solutions. I am looking forward to working alongside Taby and Jonathan as they help guide our mission of building a healthier future for all.

We also launched Beakers & Brews this month, a new event series with our partners at VWR, designed to give CLS members, startup founders, service providers, and industry partners a space for practical learning and meaningful connection. We hosted our first two gatherings in San Francisco and San Diego, each pairing a Corning-led training on cell culture innovation with a networking happy hour. The energy in both rooms was a reminder of how much our community values opportunities to learn from each other and build relationships that strengthen the ecosystem.

Looking Ahead

May reinforced something I keep coming back to. The story of California life sciences is a story of leadership, and leadership requires both the work happening inside our labs and companies and the work happening alongside policymakers in Sacramento and Washington. The Sector Report gives us the clearest possible picture of what this ecosystem produces, and it is also a reminder that the conditions making this work possible cannot be taken for granted. Hill Day was our community showing up to defend those conditions, the long-term commitments being made by companies like Pfizer are a reminder of what is at stake, and the new colleagues joining our board and the members coming together at events like Beakers & Brews are how we keep building on this foundation.

I am grateful for the colleagues and partners who make all of this possible, and I look forward to sharing more next month.

Mike Guerra is President and CEO of California Life Sciences (CLS), California’s most influential life sciences trade association, representing more than 1,300 member companies. He chairs the Council of State Bioscience Associations and sits on multiple industry boards, working to advance California’s position as the world’s leading life sciences innovation ecosystem. Mike champions effective public policy at the national, state, and local levels, and is a steadfast advocate for the entrepreneurs and businesses driving life sciences forward in California.